Salix Expects Two NDA Submissions In Fourth Quarter For Gastrointestinal Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm’s granulated mesalamine is in development for ulcerative colitis, while its partner, Wilmington, plans to file metoclopramide-Zydis for gastroesphageal reflux.